Updated:
Magee-Womens Research Institute and Foundation
The Magee-Womens Research Institute and Foundation was established in 1992 by UPMC and the University of Pittsburgh to create a dedicated research arm for...
Magee-Womens Research Institute and Foundation
The Magee-Womens Research Institute and Foundation was established in 1992 by UPMC and the University of Pittsburgh to create a dedicated research arm for Magee-Womens Hospital. CEO Michael Annichine and Executive Director Yoel Sadovsky oversee a unique not-for-profit structure where research funding flows through an independent institute while clinical trials and patient access run through the affiliated hospital system. The foundation deploys its endowment through a mix of publicly traded securities, commodities exposure via the UPMC Master Trust Fund, and direct research grants focused on early-stage women's health innovations. Its partnership with WHAM (Women's Health Access Matters) places it inside the WHAM Investment Collaborative, a network of multibillion-dollar funds targeting fertility, menopause, and cardiovascular treatments for women. Confirmed fund commitments include commodities units held through the UPMC Master Trust Fund and a publicly traded securities portfolio managed from Pittsburgh. The institute operates from a complex of commercial properties on Craft Avenue in Pittsburgh, including its headquarters and a separate foundation office, alongside an Erie campus. The $1 million Magee Prize, funded by the Richard King Mellon Foundation, serves as the institute's flagship research award. The executive team's dual appointments — Annichine as CEO of the foundation and Sadovsky as executive director of the institute — reflect a governance model designed to separate fundraising from scientific decision-making. Magee-Womens Research Institute and Foundation occupies a narrow structural lane: it is an endowment that functions less like an allocator and more like an in-house research funder. Its investment returns support investigator-initiated studies rather than external manager fees, and its research output flows directly into clinical practice at UPMC Magee-Womens Hospital. This closed-loop system — where the foundation funds the institute, the institute produces findings, and the hospital implements them — eliminates the translational gap that plagues broader academic medical centers.
General information
Firm type
Endowment / Foundation
Year founded
1992
Location
Region
North America
Country
United States
City
Pittsburgh
Corporate office
204 Craft Avenue, Pittsburgh, PA, United States
Additional offices
Erie, PA
Principals
Michael Annichine
Chief Executive Officer
Yoel Sadovsky
Executive Director
Richard Beigi
President of UPMC Magee-Womens Hospital
Sector focus
Frequently asked questions
Who runs investment decisions at Magee-Womens Research Institute and Foundation?
Investment decisions are managed through participation in the UPMC Master Trust Fund, which pools assets from multiple UPMC-affiliated entities. The foundation does not disclose an internal investment committee or CIO. CEO Michael Annichine oversees the foundation's overall financial strategy, while day-to-day allocation decisions sit with UPMC's treasury and investment office.
How does the Magee-Womens Research Institute and Foundation fund its research?
The foundation combines endowment returns, federal research grants (facilitated through Federal Demonstration Partnership membership), and philanthropic gifts such as the $1 million Magee Prize from the Richard King Mellon Foundation. Its publicly traded securities portfolio and commodities exposure inside the UPMC Master Trust Fund generate the investment income that supports investigator-initiated studies.
What is the relationship between the foundation and UPMC Magee-Womens Hospital?
UPMC is both the parent corporation of Magee-Womens Hospital and the foundation's primary business partner. The hospital provides clinical integration and patient access for research trials, while the foundation supplies funding for the research institute. Richard Beigi serves simultaneously as hospital president and foundation board member, maintaining operational alignment between the two entities.
Does the Magee-Womens Research Institute and Foundation operate as an endowment or a venture fund?
It operates as a not-for-profit endowment. Unlike venture-focused foundations, Magee-Womens does not take equity stakes in portfolio companies. Its capital flows into traditional asset classes — public equities, commodities, and fixed income — with returns directed to research grants rather than startup investments. The WHAM Investment Collaborative affiliation connects it to venture-oriented peers, but the foundation itself remains a grantmaker.
What investment stages does the foundation's research funding typically target?
The foundation funds early-stage, investigator-initiated research in reproductive biology, women's cancers, cardiovascular disease, and infectious diseases. This includes preclinical work and small clinical trials conducted through UPMC Magee-Womens Hospital. It does not target late-stage drug development or commercialization; that role falls to UPMC Enterprises, the health system's separate venture arm.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: